PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.42
Bid: 2.33
Ask: 2.48
Change: 0.155 (6.89%)
Spread: 0.15 (6.438%)
Open: 2.26
High: 2.48
Low: 2.26
Prev. Close: 2.25
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Stocks looking for direction before US inflation

Wed, 12th Apr 2023 08:49

(Alliance News) - Stock prices in London opened mixed on Wednesday, as caution prevailed ahead of a US inflation reading and minutes from the Federal Reserve's March meeting.

The FTSE 100 index opened up 20.87 points, 0.3%, at 7,806.59. The FTSE 250 was down 33.76 points, 0.2%, at 18,922.29, and the AIM All-Share was down 0.62 of a point at 816.23.

The Cboe UK 100 was 0.3% higher at 780.92, the Cboe UK 250 down 0.3% at 16,482.70, and the Cboe Small Companies was down 0.6% at 13,189.85.

In European equities, the CAC 40 in Paris and the DAX 40 in Frankfurt both were up 0.2%.

"A dose of caution has been injected into financial markets as investors brace for the latest reading on US inflation," said Hargreaves Lansdown analyst Susannah Streeter.

US inflation data for March will be released at 1330 BST. Markets are expecting the annual inflation rate to cool to 5.2% from 6.0%, according to FXStreet. From the previous month, consumer prices are expected to rise 0.4%, compared to 0.5% in February.

Core inflation - excluding food and energy - is expected to edge up to 5.6% annually from 5.5% in February.

"The worry is that core inflation...may be proving harder to bring down more quickly, which could harden [Federal Reserve] policymakers' resolve," HL's Streeter noted.

"Another 0.25% hike is already expected in May, and a stronger than expected core inflation reading, could tip the balance in forecasts towards yet another rate rise in June, which may set off a fresh round of equity selling, particularly for companies in the sensitive tech sector," she added.

There also will be the release of the Federal Open Market Committee meeting minutes at 1900 BST.

At its March meeting, the Fed lifted interest rates by 25 basis points to a 475-500 basis point target range, resisting the urge to pause hikes in the face of banking sector turmoil.

"There is likely to be reference to the recent banking turmoil, although comments from one Fed member have already suggested that there are no signs yet of business or consumer spending being influenced by tighter lending conditions," said interactive investor analyst Richard Hunter.

In the US on Tuesday, Wall Street had a muted session, with the Dow Jones Industrial Average ending up 0.3%, the S&P 500 flat, and the Nasdaq Composite down 0.4%.

The dollar was mixed against major currencies in early exchanges.

Sterling was quoted at USD1.2432 early Wednesday, higher than USD1.2427 at the London equities close on Tuesday. The euro traded at USD1.0931, up from USD1.0914. Against the yen, the dollar was quoted at JPY133.64, up slightly versus JPY133.61.

In Asia on Wednesday, the Nikkei 225 index closed up 0.6%. In China, the Shanghai Composite added 0.4%, though the Hang Seng index in Hong Kong was down 1.0%. The S&P/ASX 200 in Sydney closed up 0.5%.

In London's FTSE 100 index, student accommodation provider Unite added 0.7%, updating on its UK Student Accommodation Fund and London Student Accommodation joint venture's quarterly trading.

In the 2023/24 academic year, it noted "strong progress" in booking, with 90% of rooms already sold.

"Reservations are significantly ahead of recent sales cycles, reflecting strong demand from both new and existing students as well as new nomination agreements with universities," said Chief Executive Richard Smith.

The progress reinforces its confidence in rental growth of 6% to 7% for the academic year, Unite said.

Anglo American fell 1.6%.

The miner announced the value of rough diamond sales for De Beers in the third sales cycle of the year. Sales values rose to USD540 million from USD497 million in the second cycle. However, sales were down from USD566 million in the third cycle of 2022. The third cycle ran from March 27 to April 11.

"Sales were in line with expectations and we continue to see some encouraging positive trends in consumer demand for diamond jewellery, not least in China where we're beginning to see some signs of recovery in consumer confidence following the relaxation of travel restrictions," said De Beers CEO Al Cook.

Gold was quoted at USD2,016.14 an ounce early Wednesday, higher than USD2,002.83 on Tuesday.

In the FTSE 250, Tullow Oil dropped 4.0%, as Jefferies cut the stock to 'underperform' from 'hold'.

Brent oil fetched USD85.80 a barrel, higher than USD85.22.

Elsewhere, Hikma Pharmaceuticals fell 0.5% as it named Riad Mishlawi as its new chief executive officer.

Mishlawi will become CEO from September 1, and is currently the president of Hikma's Injectables business. Acting CEO Said Darwazah will step down, and resume his role as executive chair.

Among London's small-caps, De La Rue plunged 29%.

The banknote printer said it has been hurt by demand for banknotes sinking to a more than 20-year low. It expects full year adjusted operating profit for the year ended March 25 to be "a mid-single digit percentage below market expectations".

De La Rue said it is seeing signs of recovery, with a "significant number of new tenders actively underway", though the pace of a bounce back is uncertain.

De La Rue added: "The company is in discussions with its lending banks in relation to seeking an amendment to its banking covenants, reflecting the revised outlook and also reflecting the increase in the company's funding costs resulting from higher Bank of England base rates."

More positively, it expects revenue in its Authentication to top GBP100 million for the first time in the new financial year.

On AIM, ImmuPharma jumped 10%.

The specialist drug discovery and development company said it had received confirmation of a meeting with the US Food & Drug Administration. The pre-investigational new drug meeting will take place on May 16. It concerns the phase 2/3 adaptive trial study protocol for P140 in chronic idiopathic demyelinating polyneuropathy.

"We are delighted to be moving P140 into its second indication for CIDP patients who suffer from a rare disease with high unmet medical need. This is a great example of P140's broad potential," said CEO Tim McCarthy.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
14 Mar 2019 10:41

ImmuPharma Preparing For Lupuzor Drug Managed Access Programme

LONDON (Alliance News) - ImmuPharma PLC said it is in final preparations to open a managed access programme for its lupus drug Lupuzor to patients in Europe.Shares in the drug discovery and

Read more
26 Feb 2019 12:06

ImmuPharma upbeat on product from subsidiary Ureka

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Tuesday that on 25 February, the peer reviewed research journal Nature Communications published a fundamental scientific publication on the proprietary technology 'Urelix' from its subsidiary Ureka.

Read more
31 Dec 2018 12:00

ImmuPharma and Incanthera extend exclusivity period for Nucant agreement

(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on its clinical development collaboration agreement for its 'Nucant' cancer programme on Monday, with specialist oncology development partner Incanthera.

Read more
7 Dec 2018 11:26

ImmuPharma Progressing To Make Lupuzor Available To Patients

LONDON (Alliance News) - ImmuPharma PLC on Friday said it is currently in the process of making Lupuzor, its drug for the treatment of lupus, available to patients via its managed access drug said

Read more
7 Dec 2018 08:09

Immupharma plots patient recruitment for Lupzor trials

(Sharecast News) - Drug discovery and development outfit Immupharma has progressed its managed access programme on Lupzor as planned, with patient recruitment in France and the UK expected to follow the firm's analysis of regulatory processes across the EU.

Read more
26 Sep 2018 13:55

ImmuPharma still banking on Lupuzor even after failed trial

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced its interim results for the six months ended 30 June on Wednesday - a period in which its revenue remained negligible at £0.07m, but its drug candidate 'Lupuzor' demonstrated a superior response rate over placebo in its primary analysis on the full set of 202 patients.

Read more
26 Sep 2018 12:53

Wednesday broker round-up

(Sharecast News) - IAG: UBS downgrades to neutral with a target price of 705p.

Read more
26 Sep 2018 12:40

ImmuPharma Interim Loss Widens On Higher Costs And Lower Revenue

LONDON (Alliance News) - ImmuPharma PLC said on Wednesday it continues to progress its lupus treatment Lupuzor, as it saw a widened loss for the first half of 2018 due to higher costs and lower a

Read more
9 Sep 2018 10:59

Sunday share tips: Immupharma, PCF Bank

(Sharecast News) - For the 'Inside the City' column in the Sunday Times, Sabah Meddings wrote a "cautionary tale" about former biotech darling Immupharma, which last year saw its shares rise 227% over a year.

Read more
7 Sep 2018 11:43

ImmuPharma Inks Pact With Incanthera For Nucant Cancer Programme

LONDON (Alliance News) - ImmuPharma PLC said Friday it signed a clinical development collaboration for the Nucant cancer programme with Incanthera Ltd, a specialist oncology development the terms

Read more
7 Sep 2018 08:10

Immupharma to make 'blockbuster' lupus treatment available

(Sharecast News) - Pharmaceutical firm ImmuPharma on Friday signed an agreement for a managed access programme (MAP) for its "ground-breaking" new lupus treatment, Lupuzor.

Read more
14 Jun 2018 12:02

Immupharma Says P140 Peptide Shows Positive Results In CIDP Treatment

LONDON (Alliance News) - ImmuPharma PLC said Thursday that its pre-clinical studies of the P140 peptide showed positive results in the treatment of chronic inflammatory demyelinating were trading

Read more
29 May 2018 09:40

ImmuPharma Excited Despite Widened Loss As Lupuzor Makes Good Results

LONDON (Alliance News) - ImmuPharma PLC said Tuesday it continues to be "excited" by its future potential despite a widened loss for 2017.The drug development company reported a a

Read more
23 Mar 2018 11:17

ImmuPharma Prepares To Report Lupuzor Study Results In April

LONDON (Alliance News) - Drug development company ImmuPharma PLC said on Friday it has been informed by Simbec-Orion that the data-base lock for the Lupuzor pivotal phase III

Read more
25 Jan 2017 14:33

ImmuPharma trial of Lupuzor continuing smoothly

(ShareCast News) - Specialist drug discovery and development company ImmuPharma provided further details of patient participation on Wednesday, following confirmation in December that the company had successfully completed patient recruitment into its pivotal 52-week Phase III clinical trial of Lupu

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.